On October 5, 2021 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported that an abstract with preclinical data of its TriTAC-XR T cell engager platform has been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Harpoon Therapeutics, OCT 5, 2021, View Source [SID1234590836]). The meeting will be held virtually and in person in Washington, D.C. from November 10-14, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract details:
Title: TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation
Abstract #: 867
Author: Kathryn S. Kwant, Ph.D., et al.
Session Category: Novel Single-Agent Immunotherapies
Poster Presentation Date and Time: November 12, 7 a.m. – 8:30 p.m. ET
The full abstract will be released on November 9, 2021 at 8 a.m. ET and the poster will be available on Harpoon’s website following the presentation.
For more details about the SITC (Free SITC Whitepaper) Virtual Annual Meeting please visit: View Source